Prime Medicine, INC 10-Q quarterly reports

Prime Medicine, Inc. filed its Q2 2026 10-Q, detailing continued operating losses and a significant accumulated deficit, while also highlighting progress in its gene editing therapies and receiving RMAT designation.

Prime Medicine reports a net loss of $49.1 million for Q1 2026, with increased G&A expenses due to arbitration, while R&D costs decrease as the company prioritizes its in vivo liver franchise.

Prime Medicine reported a reduced net loss for the quarter and significantly increased its cash position through a public offering, while advancing its gene editing pipeline and facing a legal dispute.

Prime Medicine, Inc. announced a new CEO, a strategic shift to liver disease programs, and a significant capital raise, alongside ongoing arbitration with Beam Therapeutics.

Prime Medicine's Q1 2025 results show a net loss and raise substantial doubt about its ability to continue as a going concern, despite ongoing research and development efforts.

Prime Medicine has entered into a significant research collaboration and license agreement with Bristol Myers Squibb, including a $55 million equity investment and potential for over $3.5 billion in milestone payments.

Prime Medicine, a biotechnology firm specializing in gene editing therapies, announced its second-quarter financial results for 2024, highlighting advancements in its research and development pipeline despite facing substantial financial challenges.

Prime Medicine's first quarter 2024 results show increased spending on research and development, a successful capital raise, and progress in their gene editing programs.